We studied ten patients on hemodialysis (HD) treated in sequence with cuprophan (CU), ethylenevinylalcohol (EVAL), polyacrylonitrile (A-69) and polysulphone (PSP) membrane dialyzers. ß2-microglobulin (ß2m) was measured by radioimmunoassay in plasma and dialysate samples. Plasma concentrations were corrected for changes in extracellular volume (ECV). We also studied adsorption in vitro by incubating the above membranes with I-125-labelled ß2m. There were no changes in ß2m plasma concentration after HD with CU dialyzers, but a significant decrease was observed with the other membranes tested. Filtration of ß2m across the dialyzer was absent with CU and minimal with EVAL. However, large amounts were recovered from dialysate with the high-permeability dialyzers, AN-69 and PSP. In vitro studies showed that maximal adsorption capacity was obtained with AN-69 (73%) compared to 9% with CU, 4% with EVAL and 7% with PSP. In summary, ß2m clearance with PSP is achieved through greater removal of this protein by mass transport across the membrane. The mechanism by which ß2m is removed from blood during AN-69 dialysis seems to include both adsorption to and filtration by the membrane itself.
KachelH.G., AltmeyerP., BaldamusC.A., KochK.M.Deposition of an amyloid-like substance as a possible complication of regular dialysis treatment.Contr Nephrol1983; 36: 127–32.
SpertiniF., WautersJ.P., PoulenasI.Carpal tunnel syndrome: a frequent, invalidating, long-term complication of chronic hemodialysis.Clin Nephrol1984; 21: 98–101.
7.
SchwarzA., KellerF., SeyfertS., PöllW., MolzahnM., Dis-tlerA.Carpal tunnel syndrome: a major complication in long-term hemodialysis patients.Clin Nephrol1984; 22: 133–7.
8.
AssenatH., CalemardE., CharraB., LaurentG., TerratJ.C., VanelT.Hemodialyse, syndrome du canal carpien et substance amyloide.Nouv Press Med1980; 9: 1715.
9.
GejyoF., YamadaT., OdaniS.. A new form of amyloid protein associated with chronic hemodialysis was identified as (β-microglobulin. Biochem.Biophys Res Commun1985; 129: 701–6.
10.
VicentC., RevillardJ.P., GallandM., TraegerJ.Serum β2-microglobulin in hemodialyzed patients.Nephron1978; 21: 260–8.
11.
GejyoF., OdaniS., YamadaT.. β2-microglobulin: a new form of amyloid protein associated with chronic renal hemodialysis.Kidney Int1986; 30: 385–90.
12.
BommerJ., SeeligP., SeeligR., GeerlingsG., BommerG., RitzE.Determinations of plasma β2-microglobulin concentration: possible relation to membrane biocompatibility.Nephrol Dial Transplant1987; 2: 22–5.
13.
FlögeJ., GranollerasC., BingelM.. β2-microglobulin kinetics during haemodialysis and haemofiltration.Nephrol Dial Transplant1987; 1: 223–9.
14.
VandenbrouckeJ.M., JadoulM., MaldagueB., HuauxJ.P., NoelH., van Ypersele de StrihouC.Possible role of dialysis membrane characteristics in amyloid osteoarthropathy.Lancet1986; 1: 1210–1.
BernierG.M., ConradM.E.Catabolism of human β2-microglobulin by the rat kidney.Am J Physiol1969; 217: 1359–62.
22.
MogensenC.E., SoilingK.Studies on renal tubular protein reabsorption partial and near complete inhibition by certain amino acids.Scand J Clin Lab Invest1977; 37: 377–486.
GejyoF., HommaN., SuzukiY., ArakawaM.Serum levels of β2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis.N Engl J Med1986; 314: 585–6.
25.
SchardijnG.H.C., Statius van EpsL.W.β2-microglobulin: its significance in the evaluation of renal function.Kidney Int1987; 32: 635–41.
